Joining Wyeth in 2000 in the UK, Melanie led the phase III clinical development of a live attenuated intranasal influenza vaccine. In addition, she contributed to several vaccine projects in early development involving adjuvants, immune modulators, viral vectors and conjugate technology.
In 2004 she joined Sanofi Pasteur in Lyon, France where she initially led the clinical influenza franchise having oversight of the clinical development of several differentiated seasonal influenza vaccine and pandemic vaccines. She then led the clinical development of a candidate dengue vaccine moving into phase III. Subsequently, she became the Head of Clinical Development for a portfolio of vaccine projects managed out of the EU site. In 2013 she took on a broad role of Chief Medical and Clinical Officer Dengue having responsibility for the clinical development and licensure of the candidate Dengue vaccine.
In 2016 she joined Janssen Vaccines and prevention in the role of Head Late Development, Clinical and Medical Affairs overseeing several vaccines in development including for Ebola, HIV, RSV and E. coli.
Prior to joining industry, Melanie worked as a clinical virologist and conducted research at the Health Protection Agency in London in the field of RSV and HSV.
Melanie obtained her medical degree from University College, London in 1993. She also obtained a Bachelor of Science in Molecular Biology from University College, London and a Masters in Medical Virology from Imperial College, London.